A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE)

  • STATUS
    Recruiting
  • End date
    Mar 27, 2026
  • participants needed
    132
  • sponsor
    UNICANCER
Updated on 27 April 2022
cancer
nitrosoureas
measurable disease
lipase
glomerular filtration rate
metastasis
neutrophil count
cancer chemotherapy
ewing's sarcoma
immunomodulators
sarcoma of bone

Summary

INDICATION

Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas and chordomas and either bone or soft tissue metastatic CIC-rearranged sarcomas

Description

METHODOLOGY

Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind placebo-controlled trial, with 5 cohorts: cohort A: Osteosarcoma, cohort B: Ewing sarcoma, cohort C: Chondrosarcoma, cohort D : chondroma, cohort E: CIC-rearranged sarcoma. Cohort A, B and C will involve a total of 36 patients (24 Regorafenib + 12 placebo), cohort D a total of 24 evaluable patients (16 Regorafenib + 8 placebo) and cohort E will involve a total of 27 evaluable patients (18 Regorafenib + 9 placebo).

159 patients who meet the eligibility criteria will be randomly assigned in a 2:1 ratio to the following treatment groups :

The Arm A:

Regorafenib (160 mg/d) once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .

Patients receiving regorafenib who experience disease progression and for whom in the investigator opinion, treatment with regorafenib is providing clinical benefit, may continue the treatment following consultation with the study coordinator and the sponsor.

The Arm B:

Placebo plus BSC until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.

Patients will be stratified at randomization according to histology .

Details
Condition Ewing Sarcomas, Chondrosarcomas, Osteosarcomas, Chondroma, CIC-Rearranged Sarcoma
Treatment Placebo, Regorafenib
Clinical Study IdentifierNCT02389244
SponsorUNICANCER
Last Modified on27 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must have histologically confirmed diagnosis of bone sarcoma (osteosarcoma, Ewing sarcoma of bone, chondrosarcoma or chordoma)
Patients with confirmed disease progression at study entry
Metastatic disease not amenable to surgical resection or radiation with curative intent
Patients must have measurable disease
Prior treatment
at least one, but no more than two prior chemotherapy regimen for metastatic
disease for osteosarcoma, chondrosarcoma and Ewing sarcoma; neo-adjuvant
maintenance therapy are not counted towards this requirement. Chordoma not
pretreated or with 1 or 2 prior (combination) chemotherapy regimen or with one
or two prior molecularly targeted therapy, but no more than 2 prior lines of
treatment (whatever the indication) can be included. At least 4 weeks since
last chemotherapy (6 weeks in case of nitrosoureas and mitomycin C)
immunotherapy or any other pharmacological treatment and/or radiotherapy
Age ≥10 years for osteosarcomas, Ewing sarcomas and chondrosarcomas (for chordomas, patients must be ≥18 years)
Body Surface Area ≥1.30 m²
Life expectancy of greater than 3 months
Eastern Cooperative Oncology Group (ECOG) performance status <2 (Karnofsky ≥60%) for adults patients
Karnofsky scale ≥ 60% for children aged >12 years old / Lansky scale ≥60% for children aged ≤12 years old
Patients must have adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days of study treatment initiation: normal organ function as defined below
Absolute neutrophil count ≥1.5 Giga/L
Platelets ≥100 Giga/L
Hemoglobin ≥9 g/dL
Serum creatinin ≤1.5 x upper limit of normal (ULN)
Glomerular filtration rate (GFR) ≥30 ml/min/1.73 m² according to the modified Diet in Renal Disease (MDRD) abbreviated formula
Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 x ULN
Bilirubin ≤1.5 X ULN
Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in patient with liver involvement of their cancer). If Alkaline phosphatase >2.5 ULN, hepatic isoenzymes 5-nucleotidase or gamma-glutamyl transferase (GGT) tests must be performed; hepatic isoenzymes 5-nucleotidase must be within the normal range and/or GGT <1.5 x ULN
lipase ≤1.5 x ULN
Spot urine must not show 1+ or more protein in urine or the patient will require a repeat urine analysis. If repeat urinalysis shows 1+ protein or more, a 24-hour urine collection will be required and must show total protein excretion <1000 mg/24 hours
International Normalized Ratio(INR)/ Partial Thromboplastin Time (PTT) ≤1.5 x ULN
Recovery to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure related toxicity (except alopecia, anemia, and hypothyroidism)
Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy
Women of childbearing potential must have a negative serum β-HCG pregnancy test within 7 days prior randomization and/or urine pregnancy test within 48 hours before the first administration of the study treatment
Signed informed consent form by adult patients and/or patients parents/legal representatives (if age <18 years) and age appropriate assent form by the patients' parents/legal representatives obtained before any study specific procedure is conducted
Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
Patients or parents/legal representatives affiliated to the Social Security System

Exclusion Criteria

Prior treatment with any VEGFR inhibitor
Soft tissue sarcoma
Other cancer (different histology) within 5 years prior to randomization
Major surgical procedure, open biopsy, significant trauma, within the last 28 days before randomization
Cardiovascular dysfunction
Left ventricular ejection fraction (LVEF) <50%
Myocardial infarction <6 months before study
Cardiac arrhythmias requiring therapy
Uncontrolled hypertension
Congestive heart failure (New York Heart Association [NYHA]) ≥2
Unstable angina or new-onset angina
Severe hepatic impairment (Child-Pugh C)
Ongoing infection > Grade 2 according to NCI-CTCAE v4.0
Known history of human immunodeficiency virus (HIV) infection
Arterial or venous thrombotic or embolic events such as cerebrovascular accident
Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy
(including transient ischemic attacks), deep vein thrombosis, or pulmonary
Difficulties with swallowing study tablets
embolism within the last 6 months before randomization
Prior anticancer therapy, including radiotherapy, endocrine therapy, immunotherapy, chemotherapy (CT) within the last 4 weeks (6 weeks for nitrosoureas and mitomycin C), or other investigational agents ; Concomitant antalgic palliative radiotherapy allowed
Concurrent enrolment in another clinical trial in which investigational therapies are administered
Known hypersensitivity to the active substance or to any of the excipients
Pregnant women, women who are likely to become pregnant or are breast-feeding
For adult patients, individual deprived of liberty or placed under the authority of a tutor
Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Patients with history of non compliance to medical regimens or unwilling or unable to comply with the protocol
Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
Non-healing wound, non-healing ulcer, or non-healing bone fracture
Patients with evidence or history of any bleeding diathesis, irrespective of severity
Use of biological response modifiers, such as granulocyte colony stimulating factor (G-CSF), within 3 weeks of study entry
Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note